Overview
Status
Active
Registry date
2009-03-18
Share capital
50,000.00 PLN
Registered address
Mariana Pisarka 11, 03-984 Warszawa, Poland
Electronic delivery address
AE:PL-50882-62741-HBGRJ-20
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 90 days early.
- 202508/04/2026
- 202414/04/2025
- 202308/04/2024
- 202227/03/2023
- 202113/06/2022
- 202025/06/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations152 / 232
Top 66%
Results vs industry
Revenue
This companyUSD 265.53kMedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD 8.17kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 256.55kMedianUSD 873.06kAverageUSD 21.42m
Assets
This companyUSD 91.83kMedianUSD 897.46kAverageUSD 31.52m
Industry
Authorized Representatives
Agnieszka Maria Szelejewskaage 58 – President of the Management Board
Manner of representation
Each member of the management board is independently authorised to make declarations and sign on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Barbara Anna Szelejewskaage 47 | 400 | $5,402.49 | 40% |
Irena Maria Szelejewskaage 84 | 600 | $8,103.73 | 60% |
Irena Maria Szelejewska and Barbara Anna Szelejewska hold a combined 100% – the ownership structure indicates family control.
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2009-09-01.
77 1240 1082 1111 0010 2460 3433- 37 1240 6074 1111 0010 9913 4029
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $2,031$2,031 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,977$1,977 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Apr 28, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $2,031$2,031 | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Anpharm Przedsiębiorstwo FarmaceutyczneS.A. | $111,469,394.21 | anpharm.pl | ||
| Tarchomińskie Zakłady Farmaceutyczne PolfaS.A. | $102,988,448.02 | polfa-tarchomin.com.pl | ||
| VercoS.A. | $43,577,172.02 | verco.com.pl | ||
| MedicofarmaS.A. | $8,530,473.72 | medicofarma.pl | ||
| VitamaS.A. | $4,287,087.38 | vitama.pl | ||
| Munar PharmaS.A. | $85,649.72 | munar.pl | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Stg25Branch (foreign co.) | – | glagolica.eu |
FAQ
Last updated: 2026-04-16